A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Clinical trial NCT03150875 · COMPLETED
Trial details
- NCT number
- NCT03150875
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-01
- Primary completion
- 2023-02-22
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.